04688nam 22006855 450 991030034790332120200702133712.01-4939-1176-710.1007/978-1-4939-1176-9(CKB)3710000000224473(EBL)1802705(SSID)ssj0001338773(PQKBManifestationID)11704402(PQKBTitleCode)TC0001338773(PQKBWorkID)11345304(PQKB)11222333(MiAaPQ)EBC1802705(DE-He213)978-1-4939-1176-9(PPN)180627953(EXLCZ)99371000000022447320140820d2014 u| 0engur|n|---|||||txtccrManagement of Castration Resistant Prostate Cancer /edited by Fred Saad, Mario A. Eisenberger1st ed. 2014.New York, NY :Springer New York :Imprint: Humana,2014.1 online resource (336 p.)Current Clinical Urology,2197-7194Description based upon print version of record.1-322-13329-8 1-4939-1175-9 Includes bibliographical references at the end of each chapters and index.Introduction - Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities -- Evolution of Clinical States and the Castration Resistant Clinical Paradigm -- Molecular Mechanisms of Prostate Cancer Progression after Castration -- New Imaging Modalities -- Androgen Receptor Biology in Castration Resistant Prostate Cancer -- The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer -- Approaches Targeting Androgen Synthesis (CYP 17 inhibitors) -- Cytotoxic Chemotherapy (Taxanes and Taxane Combinations) -- The Emerging Role of Immunotherapy in Castrate Resistant Prostate Cancer -- Bone Targeted Therapy: Rationale and Current Status -- Radium-223 and Other Radiopharmaceuticals in Prostate Cancer -- Introduction -- Phase I/II targeted treatments -- Defining Clinical Endpoints in Castration-resistant Prostate Cancer -- Angiogenesis Inhibition in Castration Resistant Prostate Cancer -- Co-targeting Adaptive Survival Pathways -- Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer -- PARP Inhibitors -- Targeting C-Met/VEGF in Castration Resistant Prostate Cancer -- Epigenetics in Castration Resistant Prostate Cancer -- Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype -- Strategies Addressing Quality of Life: Patient Reported Outcome and Symptoms Management -- Evidence-Based Therapeutic Approaches for mCRPC patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development.This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in-depth review of proven therapeutic options, including bone-targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigation are also reviewed. The text provides up-to-date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence-based medicine. As a concise yet comprehensive summary of the current status of the field, Management of Castration Resistant Prostate Cancer serves as a very useful resource for physicians and researchers dealing with this challenging malignancy.Current Clinical Urology,2197-7194UrologyOncologyInterventional radiologyUrologyhttps://scigraph.springernature.com/ontologies/product-market-codes/H62002Oncologyhttps://scigraph.springernature.com/ontologies/product-market-codes/H33160Interventional Radiologyhttps://scigraph.springernature.com/ontologies/product-market-codes/H29021Urology.Oncology.Interventional radiology.Urology.Oncology.Interventional Radiology.616.9946306Saad Frededthttp://id.loc.gov/vocabulary/relators/edtEisenberger Mario Aedthttp://id.loc.gov/vocabulary/relators/edtMiAaPQMiAaPQMiAaPQBOOK9910300347903321Management of Castration Resistant Prostate Cancer1521889UNINA